Skip to content
LY-2183240

Structure via PubChem · Public domain (PubChem)

EntityQ6460409· pop 6· linked from 502 articles

LY-2183240

Sign in to save

Also known as N,N-dimethyl-5-[(4-phenylphenyl)methyl]-1-tetrazolecarboxamide

LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely

Chemical data

Formula
C17H17N5O
Molecular weight
307.35 g/mol
IUPAC name
N,N-dimethyl-5-[(4-phenylphenyl)methyl]tetrazole-1-carboxamide
SMILES
CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
InChIKey
GZNIYOXWFCDBBJ-UHFFFAOYSA-N
XLogP
3
Polar surface area
63.9 Ų
H-bond donors
0
H-bond acceptors
4
Formal charge
0

via PubChem

Drug data · ChEMBL

Molecule type
Small molecule

via ChEMBL · EBI

Wikidata facts

Mass
307.14331
Show 2 more facts
chemical formula
C₁₇H₁₇N₅O
canonical SMILES
CN(C)C(=O)N1C(=NN=N1)CC2=CC=C(C=C2)C3=CC=CC=C3
Sources (2)

via Wikidata · CC0

~1 min read

Encyclopedic overview

3 sections
Contents
  • See also
  • References
  • Further reading

LY-2183240 is a drug which acts both as a potent inhibitor of the reuptake of the endocannabinoid anandamide and as an inhibitor of fatty acid amide hydrolase (FAAH), the primary enzyme responsible for degrading anandamide. This leads to markedly elevated anandamide levels in the brain, and LY-2183240 has been shown to produce both analgesic and anxiolytic effects in animal models. While LY-2183240 is a potent inhibitor of FAAH, it has relatively poor selectivity and also inhibits several other enzyme side targets. Consequently, it was never developed for clinical use, though it remains widely used in research, and has also been sold as a designer drug.

==See also== Endocannabinoid reuptake inhibitor FAAH inhibitor BIA 10-2474 PF-04457845 URB-597

Excerpted from Wikipedia’s “LY-2183240” article, available under the CC BY-SA 4.0 licence.

Available in 6 languages

via Wikidata sitelinks · CC0